Serac to present data from DETECT study
Company will present vital findings at SRI annual meeting
Read Moreby John Pinching | Jan 19, 2024 | News | 0
Company will present vital findings at SRI annual meeting
Read Moreby John Pinching | Dec 6, 2022 | News | 0
Clinical trial has received regulatory approval and involves endometriosis candidate SN132D
Read Moreby Anna Smith | Jul 12, 2019 | News | 0
Currently, endometriosis treatment options are limited to surgical removal of lesions or medical management to suppress ovarian hormone production.
Read Moreby Anna Smith | Apr 2, 2019 | News | 0
The current average time for an endometriosis diagnosis can be as long as seven years.
Read Moreby Selina McKee | Jul 25, 2018 | News | 0
AbbVie and Neurocrine have announced the US approval of Orilissa, the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain.
Read Moreby Selina McKee | Apr 12, 2018 | News | 0
The US Food and Drug Administration has extended its review of AbbVie and Neurocrine’s experimental uterine pain drug elagolix by three months.
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479